DAX-0,14 % EUR/USD-0,14 % Gold0,00 % Öl (Brent)0,00 %

New Data Published in Aesthetic Plastic Surgery Explores the Use of the RECELL System in Combination with Dermabrasion to Treat Acne Scars

Nachrichtenquelle: Business Wire (engl.)
19.09.2019, 01:00  |  553   |   |   

AVITA Medical (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization of innovative therapies leveraging the healing properties of a patient’s own skin, announced today data published in Aesthetic Plastic Surgery by the Department of Plastic Surgery at Peking Union Medical College Hospital exploring the use of the RECELL Autologous Cell Harvesting Device (RECELL System) in combination with dermabrasion to treat facial acne scars.1

The retrospective study analyzes the healing time and rate of postoperative complications of 78 patients with acne scars treated using dermabrasion with and without the RECELL System, revealing a statistically significant difference in healing time (P\ 0.001) between the two treatment regimens. Acne scars treated using dermabrasion healed more quickly on average with RECELL (5.27 ± 1.086 days) than without RECELL (average healing time of 12.30 ± 1.725 days). In addition, there were no postoperative complications, such as pigmentation and scar hyperplasia, and higher patient satisfaction rates (P< 0.001) for those patients treated with RECELL.

“It’s exciting to see physicians worldwide interested in studying the possible application of the RECELL System to advance patient care across a broad range of treatments,” said Andrew Quick, AVITA Medical’s Chief Technology Officer. “We look forward to continued collaboration within the global medical community as we explore the full potential of this regenerative technology platform to address unmet medical needs.”

Other recent publications investigating the use of the RECELL System in the treatment of dermatological conditions, include:

The RECELL System, which uses a small amount of a patient’s own skin to prepare Spray-On Skin Cells at the point of care, is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute thermal burns in patients 18 years and older. In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, acute and chronic wounds, scars, and vitiligo.

Diesen Artikel teilen
Seite 1 von 3
Wertpapier

Mehr zum Thema
Klicken Sie auf eines der Themen und seien Sie stets dazu informiert. Mehr Informationen hier.
EuroChinaMIT


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel

Nachrichten zu den Werten

ZeitTitel
30.09.19